Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : IV/IM Susceptible infections 0.5-2 g 4-8 hrly. Surgical prophylaxis 1 or 2 g, to be given 30-60 mins pre-op, then 1 or 2 g 6 hrly for 24-48 hr.
Dosage Details
Prophylaxis of surgical infections
Adult: 1 or 2 g IV or IM, given 30-60 minutes before surgical incision followed by 1 or 2 g every 6 hr for 24-48 hr. For procedures involving implantation of prosthetic devices, may continue treatment for up to 72 hr.
Child: >3 mth: 50-100 mg/kg/day IV or IM, given 30-60 minutes before surgical incision; followed by every 6 hr for 24-48 hr. For procedures involving implantation of prosthetic devices, may continue treatment for up to 72 hr.

Susceptible infections
Adult: 0.5-2 g every 4-8 hr depending on severity of the infection. Dose may be given by deep IM, slow IV over 3-5 minutes or by intermittent or continuous infusion.
Child: >1 mth: 50-100 mg/kg/day in divided doses; up to 150 mg/kg/day may be used in severe infections.
Renal Impairment
CrCl Dosage
<2 Initially, 1-2 , followed by 0.25-0.75 g every 12 hr.
10-25 Initially, 1-2 g, followed by 0.5-1.25 g every 8 hr.
2-10 Initially, 1-2 g, followed by 0.5-1 g every 12 hr.
25-50 Initially, 1-2 g, followed by 0.75-2 g every 8 hr.
50-80 Initially, 1-2 g, followed by 0.75-2 g every 6 hr.
Incompatible with aminoglycosides and metronidazole.
Special Precautions
Hypersensitivity to penicillins; renal impairment; porphyria. Monitor renal and haematologic status. May cause bleeding (reversible with vitamin K admin).
Adverse Reactions
Nausea; vomiting; diarrhoea; hypersensitivity reactions; nephrotoxicity; convulsions; CNS toxicity; pseudomembranous colitis; hepatic dysfunction; haematologic disorders; pain at inj site (IM); thrombophloebitis (IV infusion); superinfection with prolonged use.
Drug Interactions
Disulfiram-like interaction with alcohol. May enhance hypoprothrombinemic response to anticoagulants. Renal clearance reduced by probenecid.
Lab Interference
Positive direct antiglobulin Coombs' test; falsely high values with Jaffe method of measuring creatinine concentrations; transient increases in liver enzyme values.
Description: Cefamandole inhibits the final cross-linking stage of peptidoglycan production through binding and inactivation of transpeptidases on the inner surface of the bacterial cell membrane thus inhibiting bacterial cell wall synthesis.
Absorption: Poorly absorbed from the GI tract.
Distribution: 70% bound to plasma proteins. Widely distributed in body tissues and fluids including bone, joint fluid and pleural fluid.
Excretion: Plasma half-life ranges from 0.5-1.2 hr depending on the route of admin. Rapidly excreted unchanged by glomerular filtration and renal tubular secretion.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefamandole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in